Hongyuan Zhang
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 22, 2026
Targeting P21-Activated Kinase 2 as a Novel Therapeutic Approach to Mitigate Endoplasmic Reticulum Stress in Heart Failure With Preserved Ejection Fraction.
Journal: Journal of the American Heart Association
Published: January 10, 2025
Stabilisation of PRCP by deubiquitinase-targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy.
Journal: British journal of pharmacology
Published: November 29, 2024
Advancing antihypertensive drug development.
Journal: British journal of pharmacology
Published: November 22, 2024
Rational discovery of therapeutic PAK1 allosteric activators.
Journal: Cell
Published: January 27, 2024
Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II.
Journal: Journal of the American Heart Association
Published: June 15, 2023
The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease.
Journal: International journal of drug discovery and pharmacology
Published: December 21, 2022
Recent Advances on Drug Development and Emerging Therapeutic Agents Through Targeting Cellular Homeostasis for Ageing and Cardiovascular Disease.
Journal: Frontiers in aging
Published: March 02, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026